Skip to main content

Chronic Kidney Disease

Nephrology
88
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
8
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
17
1
29
2
20
19
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1467%
Vaccine
524%
Peptide
15%
Monoclonal Antibody
15%
+ 176 programs with unclassified modality

Chronic Kidney Disease is a $13.3B market (indication-attributable estimate) in mature/consolidating phase, dominated by two SGLT2 inhibitors representing 94% of spending.

$13.3B (indication-attributable estimate; raw spend across matched products was $14.0B, split evenly across approved indications) marketMature→ Stable30 products15 companies

Key Trends

  • SGLT2 inhibitors (dapagliflozin, empagliflozin) have become standard of care, driving 94% of Part D spend
  • Legacy phosphate binders and vitamin D analogs face patent cliffs 2030–2031, opening biosimilar/generic opportunities
  • 590 active trials signal robust pipeline activity, with 129 Phase 3 trials testing new mechanisms in CKD progression and mineral metabolism

Career Verdict

Strong career opportunity: mature market with high revenue, stable patient base, but limited blockbuster upside; ideal for those seeking established companies, commercial scale, and MSL/medical affairs roles rather than high-growth innovation bets.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1EmpagliflozinStable
$8.8B
Boehringer Ingelheim / Eli Lilly·Peak
#2DapagliflozinStable
$4.3B
AstraZeneca·Peak
#3FinerenoneGrowing
$1.1B
Bayer·Peak

Drug Class Breakdown

Sodium-Glucose Transporter 2 Inhibitors (SGLT2i)
$13.1B(98%)

Dominant; standard of care for CKD with albuminuria

Mineralocorticoid Receptor Antagonists (MRA)
$1.1B(8%)

Niche; often combined with SGLT2i for additional renal protection

Phosphate Binders (non-calcium)
$297M(2%)

Legacy segment; facing patent cliffs and generic pressure

Iron Replacement / Anemia Support
$183M(1%)

Supportive care; addresses CKD-related anemia

Vitamin D Analogs
$37K(<1%)

Minimal revenue; older mechanism

Career Outlook

Stable

CKD is a stable, high-revenue therapeutic area with limited growth but strong employment depth. SGLT2i dominance creates a bifurcated market: established players (AstraZeneca, Boehringer Ingelheim, Bayer) have secure footing and premium compensation, while legacy businesses (Sanofi, Fresenius) face erosion. Best career moves are into Commercial, Medical Affairs, and Real-World Evidence roles at market leaders; R&D specialists should focus on pipeline programs (Phase 2–3 trials) rather than legacy portfolio maintenance.

Breaking In

Aim for roles at AstraZeneca, Boehringer Ingelheim, or Abbott; start in Commercial or Clinical Operations to learn the stable CKD market, then pivot to Medical Affairs if you build nephrology expertise.

For Experienced Professionals

If 5+ years in pharma, CKD Medical Affairs or Market Access roles at established leaders offer $280K+; avoid legacy businesses facing patent cliffs unless seeking a 2–3 year wind-down role with restructuring experience.

In-Demand Skills

Real-world evidence (RWE) / outcomes research for value-based CKD managementMedical Affairs and KOL engagement in nephrologyHealth economics and reimbursement strategy (CKD-related complications drive cost)Digital health / remote monitoring (CKD patient adherence)Combination therapy strategy (SGLT2i + MRA + other mechanisms)

Best For

Medical Science Liaison (MSL) — high demand, $302K avg salary, complex nephrology KOL baseCommercial / Sales — large hiring, $232K avg, stable CKD patient populationReal-World Evidence Manager — growing emphasis on outcomes data for payer negotiationsRegulatory Affairs — ongoing Phase 3 trials and label expansions (earlier CKD stages, non-diabetic indications)Market Access / Health Economics — CKD complications drive payer interest in prevention

Hiring Landscape

$112K–$302K

CKD hiring is concentrated in commercial (1,420 jobs, avg $232K) and engineering (831 jobs, avg $205K), reflecting mature-market focus on sales execution, market access, and digital health platforms rather than discovery. Abbott, AbbVie, Takeda, and AstraZeneca lead hiring (1,029–1,499 jobs each); Medical Affairs roles command highest salary ($302K) due to complex KOL relationships in nephrology.

8,140
Open Roles
4
Companies Hiring
4
Departments

Top Hiring Companies

Abbott
1499Growing
AbbVie
1051Stable
Takeda
1048Stable
AstraZeneca
1029Stable

By Department

Commercial(17%)
$232K
Engineering(10%)
$205K
Clinical Operations(4%)
$172K
Medical Affairs(3%)
$302K

Commercial and Medical Affairs roles offer best near-term hiring and highest compensation; R&D and Manufacturing roles are smaller and may contract as legacy products face patent cliffs.

On Market (8)

Approved therapies currently available

Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
8.8B Part D
AstraZeneca
FARXIGAApproved
dapagliflozin
AstraZeneca
oral2014
4.3B Part D
Bayer
KERENDIAApproved
finerenone
Bayer
Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]oral2021
270M Part D
Sanofi
RENVELAApproved
sevelamer carbonate
Sanofi
oral2007
114M Part D
Otsuka
JYNARQUEApproved
tolvaptan
Otsuka
Vasopressin V2 Receptor Antagonist [EPC]oral2018
76M Part D
Otsuka
SAMSCAApproved
tolvaptan
Otsuka
Vasopressin V2 Receptor Antagonist [EPC]oral2009
12M Part D
Otsuka
TOLVAPTANApproved
tolvaptan
Otsuka
oral2025
3M Part D
AbbVie
ZEMPLARApproved
paricalcitol
AbbVie
Vitamin D2 Analog [EPC]intravenous1998

Competitive Landscape

59 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
21 programs
8
6
1
1
1
DapagliflozinPhase 4Small Molecule1 trial
DapagliflozinPhase 3Small Molecule1 trial
Dapagliflozin 10mg TabPhase 2/31 trial
AZD1722Phase 21 trial
AZD5718Phase 21 trial
+16 more programs
Active Trials
NCT05306210Completed1,029Est. Oct 2024
NCT05932901Completed2,682,052Est. Sep 2023
NCT07450820Recruiting14,308Est. Feb 2027
+16 more trials
Abbott
AbbottABBOTT PARK, IL
14 programs
5
1
2
3
CalcitriolPhase 41 trial
ParicalcitolPhase 41 trial
ParicalcitolPhase 41 trial
paricalcitolPhase 31 trial
paricalcitolPhase 31 trial
+9 more programs
Active Trials
NCT01368042Completed265Est. Jun 2013
NCT00796679Completed60Est. Jun 2011
NCT00428246Completed24Est. Jul 2007
+11 more trials
Sandoz
7 programs
1
1
1
1
1
HX575 recombinant human erythropoietin alfaPhase 4
HX575 epoetin alfaPhase 3
SBR759Phase 2
SBR759Phase 1/2
OJR520Phase 1
+2 more programs
Bayer
BayerLEVERKUSEN, Germany
7 programs
2
3
1
KERENDIA(finerenone)Phase 45 trials
BAY2327949Phase 21 trial
BAY3283142Phase 25 trials
runcaciguatPhase 21 trial
RuncaciguatPhase 11 trial
+2 more programs
Active Trials
NCT05407662Completed600Est. Jun 2023
NCT04820621Terminated5Est. Jul 2021
NCT07431294Not Yet Recruiting36Est. Dec 2026
+13 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
6 programs
3
1
1
Viekira Pak ± ribavirinPhase 41 trial
paricalcitolPhase 3
AtrasentanPhase 2
AtrasentanPhase 2
Atrasentan low dose groupPhase 2
+1 more programs
Active Trials
NCT02946034Completed10Est. Sep 2020
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
6 programs
1
SGLT2 inhibitorN/A1 trial
AvenciguatPHASE_21 trial
VicadrostatPHASE_2Small Molecule1 trial
collection of serum/capillary creatinine valuesPHASE_21 trial
EmpagliflozinPHASE_3Small Molecule1 trial
+1 more programs
Active Trials
NCT07063316Active Not Recruiting15,000Est. Sep 2026
NCT04736628Completed261Est. Sep 2023
NCT06926660Active Not Recruiting416Est. Aug 2026
+3 more trials
Colorado Therapeutics
5 programs
2
NSAIDsPhase 41 trial
Nitrate-rich beetroot juicePhase 41 trial
Facilitated Clinical Decision SupportN/A1 trial
Flow-mediated dilationN/A1 trial
Sodium bicarbonateN/A1 trial
Active Trials
NCT01767883Completed27,000Est. Jan 2016
NCT02230202Completed90Est. Mar 2016
NCT02915601Completed109Est. May 2022
+2 more trials
Angeles Therapeutics
3 programs
1
Low Volume iso-osmolar non-ionic radio contrast mediumPhase 41 trial
Bioflo Dialysis CatheterN/A
Comparison of Markers of Kidney FunctionN/A1 trial
Active Trials
NCT01403766Completed17Est. Dec 2012
NCT02476526Completed50Est. Nov 2017
Sanofi
SanofiPARIS, France
2 programs
1
CRICKET Study, Coronary Calcium Scores in Patients With Chronic Kidney DiseaseN/A1 trial
RENVELA(sevelamer carbonate)PHASE_31 trial
Active Trials
NCT00142636Withdrawn0Est. Sep 2005
NCT00267514Completed31Est. May 2007
Otsuka
1 program
1
1
TolvaptanPhase 31 trial
Active Trials
NCT02160145Completed1,370Est. Apr 2017
Hanmi Pharmaceutical
1 program
1
Simvast CRPhase 41 trial
Active Trials
NCT01564875Unknown122Est. May 2012
Astellas
AstellasChina - Shenyang
10 programs
1
1
5
ASP1585Phase 31 trial
ASP1585Phase 31 trial
ASP1585Phase 31 trial
ASP1585Phase 31 trial
ASP1585Phase 31 trial
+5 more programs
Active Trials
NCT02805348Completed144Est. Dec 2018
NCT05015998Completed45,637Est. Nov 2021
NCT05530291Completed85,259Est. Nov 2022
+7 more trials
Prevail Therapeutics
6 programs
2
2
1
EmpagliflozinPhase 3Small Molecule
LY2623091Phase 2
VolenrelaxinPhase 2
LY2623091Phase 1
LY3113593Phase 1
+1 more programs
Innovation Pharmaceuticals
5 programs
2
Darbepoetin alfaPhase 31 trial
HydrationPhase 31 trial
Collaborative Model of Primary care and Subspecialty careN/A1 trial
HydrationN/A1 trial
Point-of-care screeningN/A1 trial
Active Trials
NCT02587936Completed18,268Est. Oct 2022
NCT01766687Completed822Est. Jun 2017
NCT03595267Recruiting2,500Est. Dec 2025
+2 more trials
Biocorp
5 programs
3
2
roxadustatPhase 3Small Molecule
roxadustatPhase 3Small Molecule
RoxadustatPhase 2Small Molecule
RoxadustatPhase 2Small Molecule
RoxadustatPhase 2Small Molecule
Pharmacosmos
2 programs
1
1
Iron oligosaccharidePhase 31 trial
Monofer®Phase 11 trial
Active Trials
NCT01469078Completed18Est. Nov 2012
NCT00536666Completed182Est. Aug 2008
Biocad
1 program
1
Darbepoetin alfaPhase 31 trial
Active Trials
NCT02506868Completed196Est. Dec 2017
Pfizer
PfizerNEW YORK, NY
1 program
1
Epoetin HospiraPhase 31 trial
Active Trials
NCT01473407Completed612Est. Feb 2014
Blau Farmaceutica
1 program
1
Epoetin alphaPhase 31 trial
Active Trials
NCT01695759Terminated92Est. Jan 2018
MSD
5 programs
1
MK-0677Phase 21 trial
Gardasil® VaccineN/AVaccine1 trial
Human Papillomavirus VaccineN/AVaccine1 trial
MK-0677N/A1 trial
Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell FormationN/A1 trial
Active Trials
NCT00806676Completed67Est. Aug 2015
NCT00767897Completed72Est. Dec 2018
NCT00395291Completed49Est. May 2010
+2 more trials
Sharp Therapeutics
5 programs
1
MK-0677Phase 2
Gardasil® VaccineN/AVaccine
Human Papillomavirus VaccineN/AVaccine
MK-0677N/A
Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell FormationN/A
ProKidney
2 programs
1
1
Neo-Kidney AugmentPhase 21 trial
Renal Autologous Cell TherapyPhase 11 trial
Active Trials
NCT04115345Completed6Est. Jan 2023
NCT02525263Terminated1Est. Aug 2017
Medice
1 program
1
NicotinamidePhase 21 trial
Active Trials
NCT01200784Completed252Est. Jul 2011
Syneos Health
1 program
1
RilonaceptPhase 2
Nanogen Pharmaceutical Biotechnology
1 program
1
StimusPhase 11 trial
Active Trials
NCT05636891Completed43Est. Nov 2022
Novo Nordisk
9 programs
KBP-5074PHASE_11 trial
NNC0385-0434 A 100 mgPHASE_11 trial
somatropinPHASE_11 trial
CagrilintidePHASE_2Peptide1 trial
NNC0519-0130PHASE_21 trial
+4 more programs
Active Trials
NCT02837237Completed11Est. Jun 2017
NCT05094934Terminated60Est. Aug 2022
NCT01502137Completed21Est. Nov 2005
+6 more trials
Parexel
ParexelMA - Boston
7 programs
AZD4248PHASE_1
AZD5718PHASE_1
MEDI8367PHASE_1
VerinuradPHASE_1
VerinuradPHASE_1
+2 more programs
Opko Health
Opko HealthMIAMI, FL
7 programs
CTAP101 CapsulesPHASE_11 trial
CTAP201 InjectionPHASE_11 trial
CTA018 InjectionPHASE_21 trial
Cohort 1 CTAP101 Capsules- 60µgPHASE_2_31 trial
CTAP101 30 μg capsulesPHASE_31 trial
+2 more programs
Active Trials
NCT00888069Completed28Est. Dec 2009
NCT00792857Completed24Est. Oct 2009
NCT00742716Completed41Est. Jun 2010
+4 more trials
Baxter
6 programs
Dialysis Flow Rate Start 600mL/minN/A
Evaluation of the Peritoneal Dialysis Program in a Hospital in Chinandega, Nicaragua.N/A
Heparin free dialysis techniqueN/A
Improving Outcomes in Peritoneal DialysisN/A
Polyflux 210H dialyzerN/A
+1 more programs
Baxter International
6 programs
Dialysis Flow Rate Start 600mL/minN/A1 trial
Evaluation of the Peritoneal Dialysis Program in a Hospital in Chinandega, Nicaragua.N/A1 trial
Heparin free dialysis techniqueN/A1 trial
Improving Outcomes in Peritoneal DialysisN/A1 trial
Polyflux 210H dialyzerN/A1 trial
+1 more programs
Active Trials
NCT00962000Completed42Est. Jun 2010
NCT02270229Unknown60
NCT01318486Completed265Est. Feb 2013
+3 more trials

+29 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
GenentechRecombinant Human Growth Hormone
Bayerfinerenone
Colorado TherapeuticsNSAIDs
AstraZenecaDapagliflozin
Colorado TherapeuticsNitrate-rich beetroot juice
AbbVieViekira Pak ± ribavirin
Hanmi PharmaceuticalSimvast CR
AbbottParicalcitol
AbbottParicalcitol
GE HealthCareOmniscan
Angeles TherapeuticsLow Volume iso-osmolar non-ionic radio contrast medium
AbbottCalcitriol
NovartisHX575 recombinant human erythropoietin alfa
Bristol Myers Squibbpravastatin
Novo Nordisksomatropin

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 23,203 patients across 50 trials

NCT00194961GenentechRecombinant Human Growth Hormone

Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease

Est. completion: Dec 200715 patients
Phase 4Terminated
NCT07155694Bayerfinerenone

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

Start: Sep 2025Est. completion: Aug 202730 patients
Phase 4Not Yet Recruiting
NCT06860711Colorado TherapeuticsNSAIDs

Safety of Short-course of NSAIDs in Pediatric Patients With CKD

Start: Jul 2025Est. completion: Jun 202780 patients
Phase 4Recruiting
NCT06610526AstraZenecaDapagliflozin

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Start: Aug 2024Est. completion: May 2027731 patients
Phase 4Active Not Recruiting
NCT03826147Colorado TherapeuticsNitrate-rich beetroot juice

Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease

Start: May 2019Est. completion: Aug 202692 patients
Phase 4Active Not Recruiting
NCT02946034AbbVieViekira Pak ± ribavirin

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

Start: Feb 2017Est. completion: Sep 202010 patients
Phase 4Completed
NCT01564875Hanmi PharmaceuticalSimvast CR

Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia

Start: Dec 2010Est. completion: May 2012122 patients
Phase 4Unknown
NCT01163162AbbottParicalcitol

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

Start: Aug 2010Est. completion: Jun 201116 patients
Phase 4Completed
NCT00977080AbbottParicalcitol

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

Start: Nov 2009Est. completion: May 2011272 patients
Phase 4Completed
NCT00908310GE HealthCareOmniscan

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

Start: May 2009Est. completion: Sep 2013213 patients
Phase 4Completed
NCT02476526Angeles TherapeuticsLow Volume iso-osmolar non-ionic radio contrast medium

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

Start: Sep 2008Est. completion: Nov 201750 patients
Phase 4Completed
NCT00752102AbbottCalcitriol

Vitamin D and Coronary Calcification Study

Start: Sep 2008Est. completion: Oct 201344 patients
Phase 4Completed
NCT00632125NovartisHX575 recombinant human erythropoietin alfa

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.

Start: Jul 2008Est. completion: Sep 20101,695 patients
Phase 4Completed
NCT00384618Bristol Myers Squibbpravastatin

Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study

Start: May 2001Est. completion: Aug 2005100 patients
Phase 4Terminated
NCT00184769Novo Nordisksomatropin

Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.

Start: Jan 1998Est. completion: Dec 200516 patients
Phase 4Completed
NCT07107945Boehringer IngelheimEmpagliflozin

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Start: Dec 2025Est. completion: Jun 2029120 patients
Phase 3Recruiting
NCT07270367Bayerfinerenone

Finerenone and Cardiac Remodeling

Start: Dec 2025Est. completion: Dec 2030156 patients
Phase 3Not Yet Recruiting
NCT05901831Bayerfinerenone

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Start: Feb 2024Est. completion: Sep 2025241 patients
Phase 3Completed
NCT06244758Bayerfinerenone

Finerenone and Renal Oxidative Stress

Start: Jan 2024Est. completion: Nov 202591 patients
Phase 3Completed
NCT05425719MediBeaconMB-102

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Start: Jun 2022Est. completion: Feb 2023249 patients
Phase 3Completed
NCT03594110Boehringer IngelheimEmpagliflozin

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Start: Jan 2019Est. completion: Jul 20246,609 patients
Phase 3Completed
NCT03036150AstraZenecaDapagliflozin

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Start: Feb 2017Est. completion: Jun 20204,304 patients
Phase 3Completed
NCT02506868BiocadDarbepoetin alfa

Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients

Start: Aug 2015Est. completion: Dec 2017196 patients
Phase 3Completed
NCT02160145OtsukaTolvaptan

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Start: May 2014Est. completion: Apr 20171,370 patients
Phase 3Completed
NCT01695759Blau FarmaceuticaEpoetin alpha

Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Start: Dec 2013Est. completion: Jan 201892 patients
Phase 3Terminated
NCT02282813Opko HealthCTAP101 Capsules

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

Start: Apr 2013Est. completion: May 2015298 patients
Phase 3Completed
NCT01742611AstellasASP1585

Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Start: Mar 2013Est. completion: Apr 2015105 patients
Phase 3Completed
NCT01704079Opko HealthCTAP101 30 μg capsules

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Start: Nov 2012Est. completion: Sep 2014216 patients
Phase 3Completed
NCT01753466Innovation PharmaceuticalsHydration

The Water Intake Trial: Pilot Phase

Start: Oct 2012Est. completion: Apr 201333 patients
Phase 3Completed
NCT01742585AstellasASP1585

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Start: Oct 2012Est. completion: May 2014163 patients
Phase 3Completed
NCT01651000Opko HealthCTAP101 30 μg capsules

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Start: Sep 2012Est. completion: Jul 2014213 patients
Phase 3Completed
NCT01576341NovartisHX575 epoetin alfa

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

Start: Apr 2012Est. completion: Jun 2015417 patients
Phase 3Completed
NCT01581073Innovation PharmaceuticalsDarbepoetin alfa

PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease

Start: Feb 2012Est. completion: Dec 2017476 patients
Phase 3Completed
NCT01473407PfizerEpoetin Hospira

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Start: Jan 2012Est. completion: Feb 2014612 patients
Phase 3Completed
NCT01069692NovartisSBR759

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

Start: Feb 2010115 patients
Phase 3Completed
NCT01057407AstellasASP1585

A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Start: Jan 2010Est. completion: Sep 2010110 patients
Phase 3Completed
NCT01071070Abbottparicalcitol

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Start: Nov 2009Est. completion: Nov 2010216 patients
Phase 3Completed
NCT01017276AstellasASP1585

A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis

Start: Nov 2009Est. completion: Sep 201035 patients
Phase 3Completed
NCT00985426Dynavax TechnologiesHEPLISAV-B

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Start: Sep 2009Est. completion: Jan 2012521 patients
Phase 3Completed
NCT00892749AstellasASP1585

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Start: May 2009Est. completion: Sep 2010248 patients
Phase 3Completed
NCT00497146Abbottparicalcitol

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

Start: Feb 2008Est. completion: Mar 2012227 patients
Phase 3Completed
NCT00503698Novo Nordisksomatropin

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

Start: Jul 2007Est. completion: Dec 2008712 patients
Phase 3Terminated
NCT00536666PharmacosmosIron oligosaccharide

A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients

Start: May 2007Est. completion: Aug 2008182 patients
Phase 3Completed
NCT00267514Sanofisevelamer carbonate

Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients

Start: Jan 2006Est. completion: May 200731 patients
Phase 3Completed
NCT05998837AstraZenecaDapagliflozin 10mg Tab

GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Start: Apr 2021Est. completion: Sep 202434 patients
Phase 2/3Completed
NCT01219855Opko HealthCohort 1 CTAP101 Capsules- 60µg

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Start: Oct 2010Est. completion: Nov 201178 patients
Phase 2/3Completed
NCT01204528AbbottZemplar

Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease

Start: Sep 2010Est. completion: Jul 201336 patients
Phase 2/3Completed
NCT00245388Bristol Myers Squibbpravastatin

Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

Start: Apr 2002Est. completion: Jul 2002330 patients
Phase 2/3Completed
NCT06926660Boehringer IngelheimVicadrostat

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Start: Jul 2025Est. completion: Aug 2026416 patients
Phase 2Active Not Recruiting
NCT06717698Novo NordiskNNC0519-0130

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Start: Dec 2024Est. completion: Sep 2026465 patients
Phase 2Recruiting

Related Jobs in Nephrology

Senior Director, Sales Training & Effectiveness

Mineralys TherapeuticsMineralys Therapeutics
Remote
3d ago
$215K - $250K/yr

Digital Center of Excellence Project Manager

Mineralys TherapeuticsMineralys Therapeutics
Remote
5d ago
$140K - $157K/yr

Machine Learning Application Engineer II

Maze TherapeuticsMaze Therapeutics
South San Francisco, CA
1w ago
$154K - $188K/yr

Vice President, Talent Management

Mineralys TherapeuticsMineralys Therapeutics
Remote
1w ago
$240K - $270K/yr

Executive Director, Clinical Development

Mineralys TherapeuticsMineralys Therapeutics
Remote
1w ago
$340K - $370K/yr

Medical Science Liaison

NateraNatera
Remote
2w ago
$150K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

20 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 23,203 patients
30 companies competing in this space

Related Indications

End Stage Renal Disease(203)Renal Impairment(142)Kidney Transplantation(136)Chronic Kidney Diseases(71)Renal Insufficiency(66)Acute Kidney Injury(66)Kidney Diseases(46)Renal Transplantation(45)Kidney Transplant(41)Kidney Failure, Chronic(37)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.